ARTICLE | Clinical News
Evista raloxifene: Phase III data
June 26, 2006 7:00 AM UTC
Eli Lilly and Co. (LLY), Indianapolis, Ind. Product: Evista raloxifene Business: Cancer Molecular target: Estrogen receptor Description: Selective estrogen receptor modulator (SERM) Indication: Preve...